Dipyridamole thallium-201 scintigraphy: An excellent alternative to exercise scintigraphy  by Beller, George A.
1642 
Editorial Comment 
Dipyridamole Thallium-201 
Scintigraphy: An Excellent 
Alternative to Exercise 
Scintigraphy* 
GEORGE A. BELLER, MD, FACC 
Charlottesville, Virginia 
Intravenous infusion of dipyridamole is an acceptable alter- 
native to physical exercise for myocardial imaging with 
thallium-201. The coronary dilating effect of dipyridamole 
results in a substantial increase in regional blood flow to 
areas perfused by normal coronary vessels, but abnormal 
flow reserve is observed in areas supplied by stenotic vessels 
(1). This inhomogeneity of flow is detected by abnormal 
thallium uptake when the radionuclide is injected during the 
peak vasodilative effect of the drug. Redistribution occurs in 
areas of viable, but hypoperfused, myocardial regions, com- 
parable to what is observed with exercise scintigraphy. 
Reported studies (2-6) have demonstrated that the sensitiv- 
ity and specificity of dipyridamole thallium imaging for 
detecting coronary artery disease are in the range of 80% to 
90%. In studies (3,7) in which the results of dipyridamole and 
exercise scintigraphy were compared in the same patients, 
sensitivity and specificity values were not significantly dif- 
ferent. As with exercise imaging, computer-assisted quanti- 
tative approaches to assessment of thallium uptake and 
subsequent washout have been shown to improve sensitivity 
and specificity (5). Oral administration of 300 to 400 mg of 
dipyridamole has been shown to yield scintigraphic results 
comparable to those of intravenous dipyridamole infusion 
(8), although side effects are greater. 
Detection of coronary artery disease. Because sensitivity 
and specificity values for detecting coronary artery disease 
with dipyridamole thallium scintigraphy are comparable to 
values obtained with exercise scintigraphy, the pharmaco- 
logic “stress test” should be strongly considered in patients 
who are deemed unable to exercise because of such noncar- 
disc abnormalities as peripheral vascular disease, arthritis, 
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previous stroke and orthopedic problems. Similarly, dipyr- 
idamole scintigraphy should be considered in individuals 
who are strongly suspected to have underlying coronary 
artery disease despite a normal exercise myocardial perfu- 
sion scan at suboptimal heart rate responses. Some patients 
have poor motivation to exercise or are significantly decon- 
ditioned and, thus, may not reach a double (rate-pressure) 
product sufficient to yield a diagnostic test. 
Casale et al. (9) have recommended combining a low level 
treadmill exercise with intravenous dipyridamole thallium- 
201 imaging whenever possible in order to achieve fewer 
noncardiac side effects, a higher heart to background ratio 
and a higher incidence of clinical electrocardiographic isch- 
emia than with dipyridamole alone. 
Prognostic value. Dipyridamole thallium-201 scintigraphy 
has been shown to provide useful prognostic information in 
patients with coronary artery disease, particularly those who 
are undergoing risk assessment prior to peripheral vascular 
or aortic surgery (10-13). Leppo et al. (10) reported that the 
presence of thallium redistribution on dipyridamole thallium 
scintigrams performed before hospital discharge in survivors 
of myocardial infarction was the most significant predictor of 
subsequent death, reinfarction or unstable angina. In that 
study the standard submaximal exercise test was a less 
sensitive predictor of cardiac events than was dipyridamole 
thallium imaging. Boucher et al. (11) first reported the 
application of dipyridamole thallium imaging for preopera- 
tive risk stratification in patients with peripheral vascular 
disease undergoing vascular surgery. They found that in 
patients with a prior history of angina or myocardial infarc- 
tion, the presence of thallium redistribution on dipyridamole 
scintigrams preoperatively was superior to any other clinical 
variable in predicting perioperative cardiac death, infarction, 
unstable angina or ischemic pulmonary edema. In that study, 
50% of patients with redistribution on preoperative dipyri- 
damole thallium scintigrams had a perioperative cardiac 
event. The Massachusetts General Hospital group (12,13) 
subsequently confirmed these earlier results. However, they 
showed that because patients scheduled for vascular surgery 
who had no clinical variables of prior myocardial infarction, 
congestive heart failure, angina pectoris or diabetes mellitus 
had a low likelihood of a perioperative cardiac event, dipyr- 
idamole thallium imaging was not of great value in risk 
stratification in this group. These patients could already be 
considered as having a low risk on clinical criteria alone. In 
contrast, in patients who had one or more of these clinical 
markers, the presence of redistribution on preoperative 
dipyridamole thallium scans predicted an increased likeli- 
hood of a perioperative event. It has been estimated that 
dipyridamole thallium imaging will not provide added prog- 
nostic value in 50% of patients scheduled for vascular 
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surgery because a very high or low cardiac event rate 
postoperatively can be predicted by knowledge of clinical 
information alone ( 13). 
The present study. In the present issue of the Journal, 
Younis et al. (14) report on their evaluation of the prognostic 
utility of dipyridamole thallium-201 imaging in 107 asympto- 
matic patients, including 33 with a previous myocardial 
infarction and 47 with prior bypass surgery or angioplasty. In 
nearly one half of the patients, the indications for the 
dipyridamole thallium test were symptomatic peripheral 
vascular disease (n = 28) and preoperative clearance for 
major noncardiac surgery (n = 26). Fifty-one patients had 
poor exercise tolerance. Despite the heterogeneity of this 
patient cohort, the authors found that by stepwise logistic 
regression analysis, a reversible thallium defect was the only 
significant predictor of subsequent cardiac events in the 14 
months of follow-up. Of the 13 asymptomatic patients who 
subsequently died or had a nonfatal infarction, 12 had a 
reversible dipyridamole thallium defect at the index imaging 
study. None of the 36 patients with a normal dipyridamole 
thallium scan died or had a nonfatal infarction. The majority 
of patients who died or had a subsequent nonfatal infarction 
had underlying multivessel coronary artery disease. These 
findings are remarkably similar to the findings of reported 
prognostic studies (15-18) utilizing exercise thallium-201 
scintigraphy, as pointed out by the authors. These observa- 
tions are also similar to those made in a previous study by 
Younis et al. (19) assessing the prognostic value of dipyri- 
damole thallium scintigraphy in patients after either unstable 
angina or acute myocardial infarction. In that study, logistic 
regression analysis revealed that a reversible thallium defect 
and the extent of angiographic coronary artery disease were 
the only independent predictors of a cardiac event. 
Side effects. Intravenous infusion of dipyridamole can 
induce severe asthma in patients with lung disease and a 
history of bronchospasm. A history of asthma is a relative 
contraindication to dipyridamole thallium imaging. Patients 
receiving methylxanthines (such as theophylline) will not be 
able to undergo the test because these drugs inhibit the 
vasodilatory effect of dipyridamole secondary to adenosine 
receptor antagonism (20). Minor side effects include head- 
ache, dizziness and nausea. Approximately 30% of patients 
will experience a fall in systolic pressure of 20 mm Hg or 
greater. Chest pain will be provoked in approximately 25% 
to 30% of patients, whereas ischemic ST segment depression 
is seen only in approximately 15% to 20% of individuals 
undergoing testing. There have been rare reports of myocar- 
dial infarction and even mortality in the 24 h following 
intravenous dipyridamole infusion. These catastrophic com- 
plications were observed chiefly in patients undergoing 
testing while still in the acute phase of unstable angina. The 
angina1 chest pain and ischemic ST depression consequent to 
infusion of the vasodilator are most likely due to transmural 
coronary “steal” in the distribution of the stenotic vessel 
(21). Intravenous aminophylline will promptly reverse all 
side effects resulting from dipyridamole administration. 
Exercise or dipyridamole thallium scintigraphy for prog 
nostication? The data reported by Younis et al. (14) and 
other investigators have clearly demonstrated that high- and 
low-risk subsets can be identified by dipyridamole thallium- 
20 1 imaging and yield comparable prognostic information, as 
reported for exercise thallium scintigraphy. Therefore, 
which test should one employ once dipyridamole thallium 
imaging is granted approval for clinical use by the Food and 
Drug Administration (FDA)? Exercise stress is probably the 
preferred choice in patients who are judged able to exercise 
without apparent physical limitations. This is because non- 
imaging variables contribute independent prognostic infor- 
mation for predicting subsequent cardiac events. In a study 
of Kaul et al. (17), these other independent variables in- 
cluded the change in heart rate from rest to peak exercise, 
occurrence of ST segment depression and occurrence of 
ventricular arrhythmias on exercise. Although the number of 
segments demonstrating thallium redistribution was the best 
noninvasive predictor of future cardiac events, these other 
variables provided independent predictive information. Sim- 
ilarly, the workload achieved and the blood pressure re- 
sponse to exercise have been reported to be important 
prognostic variables. Thus, one might expect to be able to 
identify more high-risk patients employing exercise as a 
stress compared with dipyridamole infusion in which only 
scintigraphic prognostic variables are identified. 
Conclusions. There is no doubt that dipyridamole thal- 
lium-201 scintigraphy will play a clinically useful role in the 
noninvasive detection of coronary artery disease, determin- 
ing its functional severity (extent and degree of hypoperfu- 
sion) and aid in identifying high- and low-risk subgroups. 
The precise clinical indications for the test as a substitute for 
exercise stress have not been definitively ascertained, al- 
though patients with symptomatic peripheral vascular dis- 
ease with diabetes or clinical risk factors for cardiac disease 
should be prime candidates for dipyridamole thallium imag- 
ing for preoperative risk stratification. The test is relatively 
safe when cognizant of the contraindications, and side 
effects can be reversed promptly with aminophylline admin- 
istration. At this writing, the FDA still has not approved 
dipyridamole thallium scintigraphy for clinical practice, al 
though approval is anticipated in the very near future. 
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